OncoSec Medical Inc. Closes $13.6 Million Registered Direct Offering

June 8, 2015 – SAN DIEGO, /PRNewswire/ — OncoSec Medical Inc. (“OncoSec”) (NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, today announced that it has closed its previously announced registered direct offering of 2,469,091 shares of its common stock at a price of $5.50 per share on June 8, 2015.

Maxim Group acted as a financial advisor for Oncosec’s $13.6 million registered direct.


This entry was posted in Investment Banking News: Q2- 2015. Bookmark the permalink.